Valuation: Glenmark Pharmaceuticals Limited

Market Cap 639B 6.73B 5.89B 5.43B 5.03B 9.56B 9.71B 65.13B 25.33B 315B 25.28B 24.74B 1,090B P/E 2026
44.2x
P/E 2027 * 27.3x
Enterprise Value 600B 6.32B 5.53B 5.1B 4.72B 8.97B 9.11B 61.12B 23.77B 296B 23.73B 23.21B 1,023B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.61x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day+0.74%
1 week+3.42%
Current month+3.42%
1 month+4.67%
3 months+7.90%
6 months+7.91%
Current year+12.00%
1 week 2,146.55
Extreme 2146.55
2,299.05
1 month 2,109
Extreme 2109
2,299.05
Current year 1,842.8
Extreme 1842.8
2,471.05
1 year 1,793.5
Extreme 1793.5
2,471.05
3 years 661
Extreme 661
2,471.05
5 years 348.9
Extreme 348.9
2,471.05
10 years 168
Extreme 168
2,471.05
Manager TitleAgeSince
Chief Executive Officer 56 1999-12-31
President - 2023-09-14
President - -
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 2011-05-11
Director/Board Member 85 2009-08-13
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+3.42% - - 6.72B
-0.49%+1.53%+13.55%+82.58% 48.11B
-1.82%+4.86%+68.33%+117.22% 37.88B
-1.39%-0.16%-4.06%+42.16% 12.47B
+0.44%+2.83%+15.18%+96.06% 12B
+0.38%+2.76%+34.19%+120.25% 9.03B
-0.16%+1.91%+22.31%+47.95% 7.24B
+0.85%+3.87%+57.49%-1.84% 7.09B
-2.81%+17.66%-18.38%+20.93% 6.54B
-1.75%-2.06%+22.96%+132.38% 4.42B
Average -0.58%+3.70%+23.51%+73.08% 16.09B
Weighted average by Cap. -0.72%+3.85%+29.22%+84.50%

Financials

2026 2027 *
Net sales 153B 1.61B 1.41B 1.3B 1.21B 2.29B 2.33B 15.6B 6.07B 75.56B 6.06B 5.93B 261B 167B 1.76B 1.54B 1.42B 1.31B 2.49B 2.54B 17B 6.61B 82.35B 6.6B 6.46B 285B
Net income 20.53B 216M 189M 174M 162M 307M 312M 2.09B 814M 10.13B 812M 795M 35.02B 23.22B 245M 214M 197M 183M 347M 353M 2.37B 920M 11.46B 919M 899M 39.61B
Net Debt -39.29B -414M -362M -334M -309M -588M -597M -4B -1.56B -19.39B -1.55B -1.52B -67.03B -37.1B -391M -342M -315M -292M -555M -564M -3.78B -1.47B -18.31B -1.47B -1.44B -63.28B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
26-07-07 2,275.65 +0.54% 966
26-07-07 ₹2,263.45 -0.31% 17,397
26-07-06 ₹2,270.45 +2.74% 30,046
26-07-03 ₹2,209.85 +0.68% 16,784
26-07-02 ₹2,195.00 +1.73% 21,175
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,264.90INR
Average target price
2,497.27INR
Spread / Average Target
+10.26%

Quarterly revenue - Rate of surprise